[{"id":"d3344f00-f5ec-40a4-b3ab-6fb2cfceee7b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05013372","created_at":"2021-08-19T14:52:58.496Z","updated_at":"2024-07-02T16:36:06.249Z","phase":"Phase 1","brief_title":"CD147-CAR T Cells for Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05013372","lead_sponsor":"Peking University People's Hospital","biomarkers":" ALK • BSG","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["ALK • BSG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD147-CAR T cells"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2022-08-02"},{"id":"97f7a6a3-dac5-4db8-806e-543037e48995","acronym":"","url":"https://clinicaltrials.gov/study/NCT04045847","created_at":"2021-05-11T11:52:43.586Z","updated_at":"2024-07-02T16:36:45.277Z","phase":"Phase 1","brief_title":"CD147-CART Cells in Patients With Recurrent Malignant Glioma.","source_id_and_acronym":"NCT04045847","lead_sponsor":"Xijing Hospital","biomarkers":" BSG","pipe":"","alterations":" ","tags":["BSG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD147-CART"],"overall_status":"Unknown status","enrollment":" Enrollment 31","initiation":"Initiation: 05/30/2019","start_date":" 05/30/2019","primary_txt":" Primary completion: 10/30/2020","primary_completion_date":" 10/30/2020","study_txt":" Completion: 05/30/2022","study_completion_date":" 05/30/2022","last_update_posted":"2020-05-07"},{"id":"2484198c-2ffb-481a-84a9-9055d949489d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03993743","created_at":"2021-05-11T11:52:42.961Z","updated_at":"2024-07-02T16:36:56.282Z","phase":"Phase 1","brief_title":"A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular Carcinoma","source_id_and_acronym":"NCT03993743","lead_sponsor":"Xijing Hospital","biomarkers":" BSG","pipe":"","alterations":" ","tags":["BSG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD147-CART"],"overall_status":"Unknown status","enrollment":" Enrollment 34","initiation":"Initiation: 05/27/2019","start_date":" 05/27/2019","primary_txt":" Primary completion: 10/27/2020","primary_completion_date":" 10/27/2020","study_txt":" Completion: 05/27/2022","study_completion_date":" 05/27/2022","last_update_posted":"2019-08-28"}]